Executive Summary
Endocrinology Benefit-Risk Analysis
Endocrinology benefit-risk assessment is evolving rapidly with GLP-1 receptor agonists expanding beyond diabetes to obesity and cardiovascular risk reduction, SGLT2 inhibitors gaining heart failure and renal indications, and increasing scrutiny of long-term metabolic drug safety. ArcaScience's endocrinology BRA methodology addresses the unique requirements of metabolic drug development including CVOT mandates, hypoglycemia risk quantification, and weight-based endpoint analysis.
The platform integrates glycemic control endpoints (HbA1c, time-in-range from CGM data), cardiovascular outcomes, weight change dynamics, and metabolic safety signals including pancreatitis, thyroid C-cell tumors, and diabetic ketoacidosis. Endocrinology-specific models achieve 93% accuracy in hypoglycemia severity classification and automated CVOT-aligned benefit-risk assessment.
Key Takeaways
4 Endocrinology-Specific Innovations
GLP-1 RA Safety Profiling
Comprehensive safety assessment for GLP-1 receptor agonists covering GI tolerability, pancreatitis signals, thyroid C-cell tumor monitoring, and gallbladder-related events.
Hypoglycemia Quantification
Multi-level hypoglycemia risk assessment (Level 1/2/3) integrating continuous glucose monitoring data, patient-reported events, and nocturnal hypoglycemia analysis.
SGLT2 Cross-Indication BRA
Unified benefit-risk assessment across diabetes, heart failure, and CKD indications for SGLT2 inhibitors, with DKA and amputation risk contextualization.
Obesity BRA Framework
Specialized benefit-risk framework for anti-obesity medications integrating weight loss durability, cardiovascular benefit, and suicidality/neuropsychiatric safety assessment.
Whitepaper Contents
8 Comprehensive Chapters
Download
Get the Full Endocrinology BRA Methodology Guide
Complete the form below to receive the document via email.
Related Resources